DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment

Inclusion Criteria: 1. Age\>18y; 2. ECOG physical status 0-1; 3. The histologic diagnosis of stomach/gastroesophageal junction adenocarcinoma; 4. According to the RECIST 1.1 standard with measurable or evaluable lesion; 5. Accept swallow oral drug; 6. WBC≧4.0×10\^9/L;ALC≧0.8×10\^9/L;ANC≧1.5×10\^9/L;PLT≧100×10\^9/L;ALT,AST≦2.5 times of the normal limit;ALP≦2.5 times of the normal limit;TBIL﹤1.5 times of the normal limit;SCr﹤1 times of the normal limit;ALB≧30g/L; 7. The expected survival time of more than 3 months; 8. good compliance; 9. Provide written informed consent. Exclusion Criteria: 1. Vital organs (heart,liver,kidney) function is serious dysfunction; 2. Patients received organ transplantation; 3. Patients with other malignant tumors or have occurred brain metastasis; 4. Patients with history of autoimmune disease; 5. Patients in pregnancy or breast-feeding period(women of child-bearing age need to check pregnancy test); 6. Patients with acute infection disease or in chronic active stage; 7. Patients with clear history of drug allergy or belong to allergic constitution; 8. Patients received chemotherapy,radiation therapy, immunosuppressive drugs (cyclosporine A,etc.) or other immune treatment in 4 weeks; 9. Patients received other clinical trials in 4 weeks.